DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer — Stella

Recruiting

Back to Borderline-resectable Pancreatic Cancer trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(2 sites)

United States

Indiana University Medical Center, Indianapolis, Indiana

The Ohio State University, Columbus, Ohio

Key details

Sponsor

Ohio State University

Enrollment target

~50 participants

Started

October 2024

Primary completion

March 2029

Age range

19 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov